FDA Warns Public About Risks of Compounded Tirzepatide

The FDA has issued warnings regarding compounded versions of tirzepatide, the active ingredient in popular diabetes and weight-loss medications, amidst ongoing shortages of the brand-name drugs. These compounded products lack the rigorous regulatory oversight of FDA-approved versions, posing higher risks such as potential dosing errors and contamination. The agency advises that brand-name medications are generally safer and more reliable for long-term patient use.